Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
AvenCell Europe GmbH currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. While these actions are situated within 1 distinct art unit, they are being reviewed by 2 distinct examiners. This indicates that while the technical subject matter is concentrated in 1 administrative group, the company must navigate the individual perspectives of multiple officials. This situation requires a strategy that accounts for the specific preferences of different examiners within the same technical field.
LEE, YIE CHIA is the busiest examiner for the portfolio, holding responsibility for 1 pending office action. The presence of 2 distinct examiners for only 2 pending office actions means there is no overlap in examiner assignments. Practitioners should prepare for potentially different interpretations of the 1 distinct art unit's guidelines as they interact with LEE, YIE CHIA and the other assigned examiner. This approach within 1 art unit highlights the importance of tailoring arguments to individual examiner tendencies.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| COOK, LISA V | 1 | 67.6% | +9.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17911678 | A TARGETING MODULE COMPRISING PD-L1 AND/OR PD-L2 FOR USE IN A METHOD FOR STIMULATING A CHIMERIC ANTIGEN RECEPTOR MEDIATED IMMUNE RESPONSE IN A MAMMAL | LEE, YIE CHIA | 29d |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17911678 | A TARGETING MODULE COMPRISING PD-L1 AND/OR PD-L2 FOR USE IN A METHOD FOR STIMULATING A CHIMERIC ANTIGEN RECEPTOR MEDIATED IMMUNE RESPONSE IN A MAMMAL | LEE, YIE CHIA | 1642 | §112 | Non-Final OA | 29d | Pending | Sep 15, 2022 |
| 17251447 | REVERSED UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS FOR TARGETING OF DIVERSE MULTIPLE ANTIGENS AND METHOD OF MANUFACTURING THE SAME AND USE OF THE SAME FOR TREATMENT OF CANCER, INFECTIONS AND AUTOIMMUNE DISORDERS | COOK, LISA V | 1642 | §103§112DP | Non-Final OA | — | Pending | Dec 11, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial